Currently Enrolling Trials
Tafinlar is specifically indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Tafinlar is not indicated for treatment of patients with wild-type BRAF melanoma.
Mechanism of Action
Tafinlar (dabrafenib) is an inhibitor of some mutated forms of BRAF kinases, as well as wild-type BRAF and CRAF kinases. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.
Adverse events associated with the use of Tafinlar may include, but are not limited to, the following:
- Palmar-plantar erythrodysesthesia syndrome
Tafinlar is supplied as a capsule for oral administration. The recommended dose is 150 mg orally taken twice daily, approximately 12 hours apart, until disease progression or unacceptable toxicity occurs. Take either at least one hour before or at least two hours after a meal. A missed dose can be taken up to six hours prior to the next dose.
Clinical Trial Results
FDA approval of Tafinlar was based on an international, multicenter, randomized, open-label, active-controlled trial conducted in 250 patients with previously untreated BRAF V600E mutation-positive, unresectable or metastatic melanoma. Patients with any prior use of BRAF inhibitors or MEK inhibitors were excluded. Patients were randomized to receive Tafinlar 150 mg by mouth twice daily (n = 187) or dacarbazine 1,000 mg/m2 intravenously every three weeks (n = 63). The primary endpoint was progression-free survival (PFS). The number of PFS events occurred in 42 percent of the Tafinlar arm versus 65 percent of the dacarbazine arm. The median number of months to progression was 5.1 versus 2.7 months.
For additional information regarding Tafinlar or melanoma with BRAF mutations, please visit the Tafinlar web page.